Tom Lowery | Chief Scientific Officer
T2 Biosystems Inc

Tom Lowery, Chief Scientific Officer, T2 Biosystems Inc

Tom Lowery, Ph.D. has served as our Chief Scientific Officer since September 2013. Since joining our company as the first employee in February 2007, Tom has held various technical leadership roles, including assay, methods, reagents and detector development programs. By applying his extensive experience in cutting edge biochemical and biophysical methods development he played a key role in establishing T2 Biosystems’s technical capabilities and in driving the company's product strategy and development. Prior to joining T2 Biosystems, Tom conducted research at the University of California Berkeley focused on developing innovative magnetic resonance based biosensors for molecular imaging. This work was funded by the UC Graduate Research and Education in Adaptive Biotechnology program. Tom earned his Ph.D. in chemistry from the University of California, Berkeley and graduated Summa Cum Laude with a B.S. in Biochemistry and University Honors from Brigham Young University.
Tom has a record of highly productive research that includes authoring six articles as an undergraduate and 16 as a graduate student. His scientific achievements include 49 issued or pending patents, and 30 articles and book chapters in top peer-reviewed journals. These include featured research articles in Science, Clinical Chemistry, and Protein Science, a cover article in Blood, and research articles in journals like Science Translational Medicine, the Proceedings of the National Academies of Sciences USA and Journal of the American Chemical Society. He also authored the two comprehensive book chapters on T2 Biosystems’s technology, entitled “Nanomaterials-based Magnetic Relaxation Switch Biosensors” and “Nuclear Magnetic Resonance Nanotechnology: Applications in Clinical Diagnostics and Monitoring”.


World Anti-Microbial Resistance Congress USA 2018 - Day 2 @ 09:20

Keynote address: Antimicrobial Therapy for Life-Threatening Infections: Speed is Life – the devastation of a delayed diagnosis

  • We think we know, but do we? What really are the true costs of sepsis? – Mary’s Story, a 360 degree view
  • Earlier targeted antibiotic therapy with T2MR technology: It can be done
  • Utilizing same-day sepsis pathogen ID for faster therapy, enhanced stewardship, improved outcomes in practice
last published: 16/Oct/18 20:05 GMT

back to speakers